Clinical trials: Hematologic Malignancies
Multiple Myeloma
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
The purpose of the study (Part 1 and Part 2) is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that…
- Trial name
- MagnetisMM-9 (NCT05014412)
- Testing
- Elranatamab
- Where
- 50 sites in United States, Japan and 2 more
- Volunteers
- 86 people
- Sponsor
- Pfizer
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
To investigate the maximum tolerated dose (MTD), safety, pharmacokinetics, and efficacy of volasertib in combination with azacitidine in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) and…
- Trial name
- NCT01957644
- Testing
- Azacitidine, Volasertib
- Where
- 14 sites in France, Germany
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
Myeloid Leukemia, Chronic, Chronic-Phase
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib
CML requires ongoing treatment and assessment of treatment milestones in order to manage the disease properly. Dasatinib is approved for the treatment of newly diagnosed PH+ CP-CML and CML in chronic or accelerated phase or blast…
- Trial name
- DasPAQT (NCT02348957)
- Where
- 66 sites in Germany
- Volunteers
- 223 people
- Sponsor
- Onco Medical Consult GmbH
B-cell Small Lymphocytic Lymphoma Recurrent
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
This was a Phase 1 multicenter study of bendamustine, rituximab and TRU-016 (BRT) in subjects with relapsed indolent B-cell lymphoma.
- Trial name
- NCT01317901
- Testing
- TRU-016, Bendamustine, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aptevo Therapeutics
Non Hodgkin's Lymphoma, NHL
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
The goal of this study is to evaluate a new approach to immunotherapy in NHL by combining two antibodies, veltuzumab and epratuzumab.
- Conditions
- Non Hodgkin's Lymphoma, NHL, Aggressive NHL, Diffuse Large B-cell Lymphoma
- Trial name
- NCT01101581
- Testing
- Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab
- Where
- 7 sites in United States
- Sponsor
- Gilead Sciences
Acute Myeloid Leukemia
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
A Randomized, Double-blind, Multiple-Dose, Two-Cycle, Parallel-Group, Bioequivalence pretrial of Daunorubicin Cytarabine liposome for Injection in older, naive patients with Acute Myeloid Leukemia (AML).
- Trial name
- NCT04920500
- Testing
- Daunorubicin Cytarabine liposome for injection, Vyxeos、Daunorubicin Cytarabine liposome for injection
- Where
- China
- Volunteers
- 16 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Breast Cancer, Anemia
Treatment for Patients Suffering From Anemia Due to Chemotherapy
The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in female breast cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia…
- Trial name
- NCT00120692
- Testing
- Darbepoetin Alfa, Recombinant Human Erythropoietin
- Sponsor
- Amgen
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either…
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00950911
- Testing
- amg 162
- Where
- 17 sites in Czechia, United Kingdom
- Volunteers
- 35 people
- Sponsor
- Amgen
Acute Myelogenous Leukemia
A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)
This is a phase II study to evaluate the safety, feasibility and efficacy of immunotherapy with GRNVAC1 in patients with AML.
- Trial name
- NCT00510133
- Testing
- GRNVAC1
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Asterias Biotherapeutics, Inc.
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety.
- Trial name
- NCT06786533
- Testing
- Anti-FLT3 CAR-T cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Hemogenyx Pharmaceuticals LLC
NHL, Multiple Myeloma
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without…
- Conditions
- NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma
- Trial name
- NCT06119685
- Testing
- IDP-023, Rituximab, Daratumumab
- Where
- 12 sites in United States
- Volunteers
- 128 people
- Sponsor
- Indapta Therapeutics, INC.
Multiple Myeloma
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, in participants with relapsed or refractory MM who have…
- Trial name
- NCT03933735
- Testing
- TNB-383B
- Where
- 14 sites in United States, Germany
- Volunteers
- 220 people
- Sponsor
- AbbVie
Lymphoma, Multiple Myeloma
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
- Trial name
- ELOQUENT - 2 (NCT01239797)
- Testing
- Lenalidomide, Dexamethasone, Dexamethasone (Oral)
- Where
- 216 sites in United States, Australia and 21 more
- Volunteers
- 646 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Myeloid, Acute
A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Phase I Dose Escalation: Primary objective is to determine the Maximum Tolerated Dose (MTD) and the recommended dose for Phase I Extension.
- Trial name
- NCT02632721
- Testing
- Decitabine, BI 836858
- Where
- 14 sites in United States, Germany and 2 more
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Relapsed/Refractory Acute Myeloid Leukemia
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with…
- Trial name
- AMELI-01 (NCT03190278)
- Testing
- UCART123v1.2
- Where
- 8 sites in United States
- Volunteers
- 29 people
- Sponsor
- Cellectis S.A.
Multiple Myeloma
A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with…
- Trial name
- RECOMM (NCT04150289)
- Testing
- Farydak
- Where
- 7 sites in United States
- Volunteers
- 248 people
- Sponsor
- pharmaand GmbH
Anemia
Clinical Tumor Anemia Registry (TAR)
The purpose of this registry is to record information of routine treatment of anemia in cancer patients in Germany. An overview of the current treatment of anemia in German outpatient centers and hospitals will be provided.
- Trial name
- TAR (NCT01795690)
- Where
- Germany
- Volunteers
- 1,018 people
- Sponsor
- iOMEDICO AG
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
The purpose of this study is to compare the efficacy and safety of liso-cel vs Investigator's Choice options (idelalisib + rituximab or bendamustine + rituximab) in adult participants with R/R CLL or SLL, whose disease has failed…
- Trial name
- NCT06205290
- Testing
- Liso-cel, Idelalisib, Rituximab
- Where
- 48 sites in United States, Austria and 9 more
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
CML, Philadelphia Chromosome Positive (Ph+)
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
This study is to determine the number of European Leukemia Network (ELN)guideline defined treatment failure events from time of study entry in CML-CP patients with low imatinib trough concentrations treated with nilotinib.
- Conditions
- CML, Philadelphia Chromosome Positive (Ph+), Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels
- Trial name
- MACS1148 (NCT01131325)
- Testing
- nilotinib
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Lymphocytic Leukemia, Chronic
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
This multi-center, single-arm study evaluated the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide in participants with B-cell chronic lymphocytic leukemia (CLL) and favorable somatic status.
- Trial name
- NCT01271010
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 10 sites in Russia
- Volunteers
- 89 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.